Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Lynparza olaparib gBRCAm, HER2-negative high-risk early breast cancer Reimburse with clinical criteria and/or conditions Complete
Lynparza olaparib Breast Cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Lynparza Olaparib Newly Diagnosed OC Reimburse with clinical criteria and/or conditions Complete
Lynparza Olaparib metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete
Lynparza olaparib Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete
Lynparza Olaparib Ovarian Cancer Do not reimburse Complete
Lynparza (Resubmission) Olaparib Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Lyrica Pregabalin Pain, Neuropathic Do not list Complete
Lyrica Pregabalin diabetic peripheral neuropathy Do not list Complete
Macugen Pegaptanib sodium Macular degeneration, age-related Do not list Complete